Onconova Therapeutics Stock Flying on Anticipated Data
Posted on February 11, 2020 by Medtech[y] Staff
Onconova Therapeutics' stock (NASDAQ:ONTX) is on a tear in the last week, jumping over 90% on the anticipated company update being presented in February 17 at Noble Capital Markets’ Sixteenth Annual Investor Conference.
The presentation will be given by Onconova CEO, Steven Fruchtman, and based on a video on Proactive's YouTube channel, the Phase 3-stage biopharmaceutical company, with an initial focus on myelodysplastic syndromes (MDS), anticipates positive pivotal trial readout by the first half of 2020.
Onconova Therapeutics Inc (NASDAQ:ONTX) Dr. Steven M. Fruchtman sat down with Proactive’s Christine Corrado at the BIO CEO & Investor Conference in New York.
According to the company's investor presentation, the next catalyst is expected to be the Phase 3 INSPIRE Pivotal readout of data in the first half of 2020.
Aside from the US IND submission, which is anticipated by the third quarter of 2020, a Phase 2/3 combination therapy randomized study with an azacitdine control arm is scheduled to start in the second half of 2020. The company expects rapid enrollment and a response endpoint can be achieved in ~6 to 9 months after patients are enrolled.
Onconova Therapeutics posted an updated Investor Presentation for January 2020. The presentation is embedded below: